Tag Archives: baby
#437918 Video Friday: These Robots Wish You ...
Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here's what we have so far (send us your events!):
ICCR 2020 – December 26-29, 2020 – [Online]
HRI 2021 – March 8-11, 2021 – [Online]
RoboSoft 2021 – April 12-16, 2021 – [Online]
Let us know if you have suggestions for next week, and enjoy today's videos.
Look who’s baaaack: Jibo! After being sold (twice?), this pioneering social home robot (it was first announced back in 2014!) now belongs to NTT Disruption, which was described to us as the “disruptive company of NTT Group.” We are all for disruption, so this looks like a great new home for Jibo.
[ NTT Disruption ]
Thanks Ana!
FZI's Christmas Party was a bit of a challenge this year; good thing robots are totally competent to have a part on their own.
[ FZI ]
Thanks Arne!
Do you have a lonely dog that just wants a friend to watch cat videos on YouTube with? The Danish Technological Institute has a gift idea for you.
[ DTI ]
Thanks Samuel!
Once upon a time, not so far away, there was an elf who received a very special gift. Watch this heartwarming story. Happy Holidays from the Robotiq family to yours!
Of course, these elves are not now unemployed, they've instead moved over to toy design full time!
[ Robotiq ]
An elegant Christmas video from the Dynamics System Lab, make sure and watch through the very end for a little extra cheer.
[ Dynamic Systems Lab ]
Thanks Angela!
Usually I complain when robotics companies make holiday videos without any real robots in them, but this is pretty darn cute from Yaskawa this year.
[ Yaskawa ]
Here's our little christmas gift to the fans of strange dynamic behavior. The gyro will follow any given shape as soon as the tip touches its edge and the rotation is fast enough. The friction between tip and shape generates a tangential force, creating a moment such that the gyroscopic reaction pushes the tip towards the shape. The resulting normal force produces a moment that guides the tip along the shape's edge.
[ TUM ]
Happy Holidays from Fanuc!
Okay but why does there have to be an assembly line elf just to put in those little cranks?
[ Fanuc ]
Astrobotic's cute little CubeRover is at NASA busy not getting stuck in places.
[ Astrobotic ]
Team CoSTAR is sharing more of their work on subterranean robotic exploration.
[ CoSTAR ]
Skydio Autonomy Enterprise Foundation (AEF), a new software product that delivers advanced AI-powered capabilities to assist the pilot during tactical situational awareness scenarios and detailed industrial asset inspections. Designed for professionals, it offers an enterprise-caliber flight experience through the new Skydio Enterprise application.
[ Skydio ]
GITAI's S1 autonomous robot will conduct two experiments: IVA (Intra-Vehicular Activity) tasks such as switch and cable operations, and assembly of structures and panels to demonstrate its capability for ISA (In-Space Assembly) tasks. This video was recorded in the Nanoracks Bishop Airlock mock-up facility @GITAI Tokyo office.
[ GITAI ]
It's no Atlas, but this is some impressive dynamic balancing from iCub.
[ IIT ]
The Campaign to Stop Killer Robots and I don't agree on a lot of things, and I don't agree with a lot of the assumptions made in this video, either. But, here you go!
[ CSKR ]
I don't know much about this robot, but I love it.
[ Columbia ]
Most cable-suspended robots have a very well defined workspace, but you can increase that workspace by swinging them around. Wheee!
[ Laval ]
How you know your robot's got some skill: “to evaluate the performance in climbing over the step, we compared the R.L. result to the results of 12 students who attempted to find the best planning. The RL outperformed all the group, in terms of effort and time, both in continuous (joystick) and partition planning.”
[ Zarrouk Lab ]
In the Spring 2021 semester, mechanical engineering students taking MIT class 2.007, Design and Manufacturing I, will be able to participate in the class’ iconic final robot competition from the comfort of their own home. Whether they take the class virtually or semi-virtually, students will be sent a massive kit of tools and materials to build their own unique robot along with a “Home Alone” inspired game board for the final global competition.
[ MIT ]
Well, this thing is still around!
[ Moley Robotics ]
Manuel Ahumada wrote in to share this robotic Baby Yoda that he put together with a little bit of help from Intel's OpenBot software.
[ YouTube ]
Thanks Manuel!
Here's what Zoox has been working on for the past half-decade.
[ Zoox ] Continue reading
#437261 How AI Will Make Drug Discovery ...
If you had to guess how long it takes for a drug to go from an idea to your pharmacy, what would you guess? Three years? Five years? How about the cost? $30 million? $100 million?
Well, here’s the sobering truth: 90 percent of all drug possibilities fail. The few that do succeed take an average of 10 years to reach the market and cost anywhere from $2.5 billion to $12 billion to get there.
But what if we could generate novel molecules to target any disease, overnight, ready for clinical trials? Imagine leveraging machine learning to accomplish with 50 people what the pharmaceutical industry can barely do with an army of 5,000.
Welcome to the future of AI and low-cost, ultra-fast, and personalized drug discovery. Let’s dive in.
GANs & Drugs
Around 2012, computer scientist-turned-biophysicist Alex Zhavoronkov started to notice that artificial intelligence was getting increasingly good at image, voice, and text recognition. He knew that all three tasks shared a critical commonality. In each, massive datasets were available, making it easy to train up an AI.
But similar datasets were present in pharmacology. So, back in 2014, Zhavoronkov started wondering if he could use these datasets and AI to significantly speed up the drug discovery process. He’d heard about a new technique in artificial intelligence known as generative adversarial networks (or GANs). By pitting two neural nets against one another (adversarial), the system can start with minimal instructions and produce novel outcomes (generative). At the time, researchers had been using GANs to do things like design new objects or create one-of-a-kind, fake human faces, but Zhavoronkov wanted to apply them to pharmacology.
He figured GANs would allow researchers to verbally describe drug attributes: “The compound should inhibit protein X at concentration Y with minimal side effects in humans,” and then the AI could construct the molecule from scratch. To turn his idea into reality, Zhavoronkov set up Insilico Medicine on the campus of Johns Hopkins University in Baltimore, Maryland, and rolled up his sleeves.
Instead of beginning their process in some exotic locale, Insilico’s “drug discovery engine” sifts millions of data samples to determine the signature biological characteristics of specific diseases. The engine then identifies the most promising treatment targets and—using GANs—generates molecules (that is, baby drugs) perfectly suited for them. “The result is an explosion in potential drug targets and a much more efficient testing process,” says Zhavoronkov. “AI allows us to do with fifty people what a typical drug company does with five thousand.”
The results have turned what was once a decade-long war into a month-long skirmish.
In late 2018, for example, Insilico was generating novel molecules in fewer than 46 days, and this included not just the initial discovery, but also the synthesis of the drug and its experimental validation in computer simulations.
Right now, they’re using the system to hunt down new drugs for cancer, aging, fibrosis, Parkinson’s, Alzheimer’s, ALS, diabetes, and many others. The first drug to result from this work, a treatment for hair loss, is slated to start Phase I trials by the end of 2020.
They’re also in the early stages of using AI to predict the outcomes of clinical trials in advance of the trial. If successful, this technique will enable researchers to strip a bundle of time and money out of the traditional testing process.
Protein Folding
Beyond inventing new drugs, AI is also being used by other scientists to identify new drug targets—that is, the place to which a drug binds in the body and another key part of the drug discovery process.
Between 1980 and 2006, despite an annual investment of $30 billion, researchers only managed to find about five new drug targets a year. The trouble is complexity. Most potential drug targets are proteins, and a protein’s structure—meaning the way a 2D sequence of amino acids folds into a 3D protein—determines its function.
But a protein with merely a hundred amino acids (a rather small protein) can produce a googol-cubed worth of potential shapes—that’s a one followed by three hundred zeroes. This is also why protein-folding has long been considered an intractably hard problem for even the most powerful of supercomputers.
Back in 1994, to monitor supercomputers’ progress in protein-folding, a biannual competition was created. Until 2018, success was fairly rare. But then the creators of DeepMind turned their neural networks loose on the problem. They created an AI that mines enormous datasets to determine the most likely distance between a protein’s base pairs and the angles of their chemical bonds—aka, the basics of protein-folding. They called it AlphaFold.
On its first foray into the competition, contestant AIs were given 43 protein-folding problems to solve. AlphaFold got 25 right. The second-place team managed a meager three. By predicting the elusive ways in which various proteins fold on the basis of their amino acid sequences, AlphaFold may soon have a tremendous impact in aiding drug discovery and fighting some of today’s most intractable diseases.
Drug Delivery
Another theater of war for improved drugs is the realm of drug delivery. Even here, converging exponential technologies are paving the way for massive implications in both human health and industry shifts.
One key contender is CRISPR, the fast-advancing gene-editing technology that stands to revolutionize synthetic biology and treatment of genetically linked diseases. And researchers have now demonstrated how this tool can be applied to create materials that shape-shift on command. Think: materials that dissolve instantaneously when faced with a programmed stimulus, releasing a specified drug at a highly targeted location.
Yet another potential boon for targeted drug delivery is nanotechnology, whereby medical nanorobots have now been used to fight incidences of cancer. In a recent review of medical micro- and nanorobotics, lead authors (from the University of Texas at Austin and University of California, San Diego) found numerous successful tests of in vivo operation of medical micro- and nanorobots.
Drugs From the Future
Covid-19 is uniting the global scientific community with its urgency, prompting scientists to cast aside nation-specific territorialism, research secrecy, and academic publishing politics in favor of expedited therapeutic and vaccine development efforts. And in the wake of rapid acceleration across healthcare technologies, Big Pharma is an area worth watching right now, no matter your industry. Converging technologies will soon enable extraordinary strides in longevity and disease prevention, with companies like Insilico leading the charge.
Riding the convergence of massive datasets, skyrocketing computational power, quantum computing, cognitive surplus capabilities, and remarkable innovations in AI, we are not far from a world in which personalized drugs, delivered directly to specified targets, will graduate from science fiction to the standard of care.
Rejuvenational biotechnology will be commercially available sooner than you think. When I asked Alex for his own projection, he set the timeline at “maybe 20 years—that’s a reasonable horizon for tangible rejuvenational biotechnology.”
How might you use an extra 20 or more healthy years in your life? What impact would you be able to make?
Join Me
(1) A360 Executive Mastermind: If you’re an exponentially and abundance-minded entrepreneur who would like coaching directly from me, consider joining my Abundance 360 Mastermind, a highly selective community of 360 CEOs and entrepreneurs who I coach for 3 days every January in Beverly Hills, Ca. Through A360, I provide my members with context and clarity about how converging exponential technologies will transform every industry. I’m committed to running A360 for the course of an ongoing 25-year journey as a “countdown to the Singularity.”
If you’d like to learn more and consider joining our 2021 membership, apply here.
(2) Abundance-Digital Online Community: I’ve also created a Digital/Online community of bold, abundance-minded entrepreneurs called Abundance-Digital. Abundance-Digital is Singularity University’s ‘onramp’ for exponential entrepreneurs—those who want to get involved and play at a higher level. Click here to learn more.
(Both A360 and Abundance-Digital are part of Singularity University—your participation opens you to a global community.)
This article originally appeared on diamandis.com. Read the original article here.
Image Credit: andreas160578 from Pixabay Continue reading